The TAP block is a regional anaesthetic technique that blocks abdominal wall somatic afferent nerves. 1 McDonnell and colleagues demonstrated improved visual analogue scores and decreased morphine requirements within the first 24 h after bowel resection via a mid-line laparotomy in patients receiving bilateral TAP blocks. Other studies have demonstrated efficacy of TAP blocks in a variety of surgeries. 2 -8 The use of local anaesthetic infusions to provide postoperative analgesia is common. 9 One consideration in selecting a dosing regimen for any infusion is the potential for toxicity because of high intravascular concentrations of local anaesthetic. Because the TAP block is generally a bilateral block 10 involving a relatively large plane containing multiple nerves, 11 higher volumes of local anaesthetic have traditionally been used to ensure successful blockade of multiple dermatomes. 12 13 Consequently, it is not unusual for local anaesthetic administration to approach maximum recommended doses. A single injection followed with an infusion technique has the potential to result in high intravascular local anaesthetic plasma concentrations. Although there are data evaluating plasma concentrations of local anaesthetics after TAP block, 12 there is no published literature describing levels resulting from TAP block followed by continuous infusion. In preparation for a randomized controlled trial looking at the efficacy of TAP infusions, we conducted a prospective observational study to evaluate peak and mean plasma concentrations of ropivacaine during a continuous 72 h TAP ropivacaine infusion.
Methods
This study was approved by the Melbourne Health Human Research and Ethics Committee. Ropivacaine is approved for neural blockade by Therapeutics Goods Administration Australia. The study was registered with the Australian and New Zealand Clinical Trials Registry (ACTRN126080002 91381). Written informed consent was obtained from the participants. Twenty adult subjects planned for intra-abdominal cavity surgery requiring a mid-line laparotomy incision were recruited over a 1-year period. Patients were excluded if they had a history of chronic pain, opioid tolerance, renal or hepatic impairment, allergy or contraindication to ropivacaine, or the other agents included in the pain management protocol: morphine, tramadol, acetaminophen, or parecoxib.
All subjects received a standardized general anaesthetic. Before operation, subjects were given weight-determined dose of between 1 and 2 g oral acetaminophen. Fentanyl was the major intraoperative analgesic, with dose determined by the treating anaesthetist. Intraoperative analgesic adjuncts were 40 mg parecoxib and 2-3 mg kg 21 tramadol depending on age. Anaesthesia was maintained with sevoflurane or desflurane in oxygen/air mix, with positive pressure ventilation in a circle system. Choice of neuromuscular blocking agent was at the discretion of the treating anaesthetist. At the conclusion of the surgery, the anaesthetist placed bilateral TAP blocks and inserted TAP catheters. Blocks were performed or supervised by one of three experienced operators.
Insertion of TAP blocks and catheters
TAP blocks were inserted with ultrasound guidance under sterile conditions using an 18 gauge Portex Tuohy (Smiths Medical Australasia, Brisbane, Australia) needle. The appropriate approach for the TAP block was selected depending on the location of the surgical incision. Where the incision was predominantly sub-umbilical, a posterior approach TAP block was performed, with the needle insertion point midway between the costal margin and the iliac crest, on the anterior axillary line. For surgical incisions that were supra-umbilical or full abdominal length, an oblique subcostal approach TAP block was performed, which involves imaging the TAP plane in the supero-medial abdominal wall.
14 The ultrasound probe is placed parallel to the costal margin, and the needle inserted lateral and caudal to the xiphoid process. Local anaesthetic is deposited posterior to the rectus abdominis muscle, anterior to either the transversus abdominis muscle or the posterior rectus sheath, depending on which structure is present at this point. The needle is then advanced parallel to the costal margin, and progressive injections of the local anaesthetic are used to hydrodissect the plane between transversus abdominis and internal oblique muscles. This approach allows blockade of intercostal nerves as they emerge to run into the transversus plane.
This decision to target different surgical incisions with either the posterior or subcostal approach has been validated by recent studies demonstrating different dermatomal spread of local anaesthetic for the two TAP block approaches. 11 13 The insertion site for the blocks was prepared with chlorhexidine 0.5% in isopropol alcohol 70% solution and surrounded by sterile drapes. The abdominal wall was imaged using a GE Logiq E ultrasound (GE Medical Systems, Jiangsu, China) with a linear 12LRS probe (GE Yokogawa Medical Systems, Tokyo, Japan).
After successful visualization of the needle tip between the internal oblique and transversus abdominis muscles, the potential TAP space was expanded with 20 ml of ropivacaine 5 mg ml 21 . Infusion catheters (open ended catheter with three lateral eyes) were then inserted via the Tuohy needle.
TAP block and infusion ropivacaine dose
For the first four patients, the dosing regimen was as follows: † Bolus of ropivacaine 200 mg (20 ml ropivacaine 5 mg ml 21 each side). † With infusion of 14 mg h 21 (7 ml h 21 of ropivacaine 2 mg ml 21 ) each side (total infusion rate 28 mg h 21 ).
Following development of potential local anaesthetic toxicity in the fourth recruited patient, the protocol was amended to reflect a weight-based dosing regimen (Table 1) . Infusions were commenced in the recovery room, 10-20 min after the initial TAP block.
Data collection and plasma ropivacaine sampling
Data collection occurred at 6, 24, 48, and 72 h after operation.
The following parameters were collected: patient controlled analgesia morphine use in total milligrams; verbal pain scores on rest and movement (0¼no pain and 10¼worst pain imaginable); and signs or symptoms of local anaesthetic toxicity including sensory disturbance, muscle twitching, hallucinations, and perioral numbness or tingling. Peripheral venous blood samples (7 ml) were taken at 0, 2, 6, 12, 24, 48, and 72 h after TAP block. The blood was centrifuged within 1 h of sampling and the plasma frozen at Maximum dose of 7 ml h 21 each side 2208C until assayed. Total and free ropivacaine levels were assayed using gas chromatography. For total plasma concentration, 400 ml of plasma was added to a screw capped borosilicate tube along with 50 ml mepivacaine 150 mg litre 21 and 50 ml 3 M KOH, and extracted with 3 ml ethyl acetate. After vortex mixing and centrifugation, the ethyl acetate layer was transferred to a second borosilicate tube and evaporated to dryness under nitrogen at 408C. The residue was reconstituted in 100 ml of methanol and 6 ml was injected into the gas chromatograph. The gas chromatograph was a Shimadzu GC-17A (Shimadzu, Kyoto, Japan) equipped with a nitrogen-phosphorus detector and programmable temperature vaporizer with a 25 m × 0.25 mm SGE BPX-5 column (SGE Analytical Science, Melbourne, Australia). Peak area ratio of ropivacaine to the mepivacaine internal standard was used to quantify the concentration of each plasma sample against a standard curve run with each batch. The method is linear to at least 20 mg litre 21 ; within day coefficient was variation of ,5% at 1 mg litre 21 on each analysis day. Unbound ropivacaine concentrations were determined after ultrafiltration with Amicon Ultra 30K centrifugal filters (Millipore, County Cork, Ireland). The extraction was similar except that 200 ml of ultrafiltrate was used and the KOH reduced to 25 ml. After reconstituting in 100 ml methanol, the sample was again evaporated to dryness under nitrogen (at room temperature), reconstituted in 50 ml methanol, and 24 ml injected into the gas chromatograph.
Mean and standard deviation (SD) of the total and unbound plasma ropivacaine concentrations at each timepoint were calculated.
Results
Thirty-five patients eligible for the trial were identified. Twenty patients consented to participation in the trial and were recruited. The reasons for failure to recruit were patient refusal (10), trial on-hold during protocol amendment (3), and rebooking of surgery date and subsequent loss to the follow-up (2). Two subjects' results were excluded from the analysis because they did not receive the ropivacaine regimen described above.
All subjects were scheduled to undergo laparotomy requiring a mid-line surgical incision. Subject characteristics, procedures, and TAP block approach are listed in Table 2 .
At the conclusion of the surgery, TAP blocks and catheters were inserted. The TAP block approach was posterior in 7 subjects and subcostal in 11 subjects. The median (inter-quartile range) time taken to place the catheters (measured from placement of the ultrasound probe to placement of the dressings over the catheters) was 24 (18-35) min.
Visualization of the TAP, placement of the needle and insertion of bilateral catheters were successful in all subjects. Where difficulties were encountered advancing the catheter into the TAP plane, an additional 10 -20 ml of normal saline was used to further expand the TAP space.
Ropivacaine plasma concentrations
Total and unbound plasma ropivacaine levels for subcostal and posterior infusions over the 72 h of infusion are shown in Figures 1-4 . Figures 1 and 2 demonstrate total ropivacaine plasma concentrations rising rapidly after the initial ropivacaine bolus of the TAP block. Thereafter, there is a second phase of more gradual increase in total plasma ropivacaine concentration. This result has been observed before in other local anaesthetic pharmacokinetic trials, and is thought to result from a gradual increase in binding proteins that occurs in response to surgical stress. 15 -18 The mean (SD) peak total ropivacaine for subcostal infusions was 2.64 (0.39) Figures 3 and 4 illustrate the unbound plasma ropivacaine levels from 24 to 72 h. The plateau observed has been previously reported. As the local anaesthetic binds to increasing levels of protein, specifically a 1 -acid glycoprotein, the unbound local anaesthetic level plateaus at a level dependent on the clearance rate. The mean (SD) peak plasma concentration of unbound ropivacaine for posterior infusions was 0.078 (0.039), which occurred at the 24 h time point. The mean (SD) peak plasma concentration of unbound ropivacaine for subcostal infusions was 0.070 (0.025) mg litre 21 , 
Analgesia
The mean (SD) morphine use in the 72 h after operation was 154 mg (138). The large SD illustrates the significant individual variability in morphine use, highlighting one of the difficulties in using analgesia requirements as a surrogate marker for levels of pain. The median pain scores are listed in Table 3 , and show consistently higher values on movement compared with at rest.
Complications
The fourth subject recruited, a young 45 kg woman, reported symptoms of facial and arm numbness and tingling at 6 h, which she noticed following her return to the ward from recovery. Her infusion was stopped, and no signs of intravascular catheter placement were observed.
Following resolution of symptoms, the infusion was restarted at 4 ml h 21 each side. However, symptoms recurred the following day, including some muscle twitching, and the catheters were removed. Symptoms of numbness of the tip of the tongue, chin, and arms did not fully resolve until around 48 h after final cessation of the infusion. Consequently, recruitment was suspended on December 16, 2008 and an amended protocol (incorporating a weight-based dosing regimen) was submitted for ethics committee approval. Recruitment recommenced on April 3, 2009.
On review of the symptomatic subject's plasma ropivacaine levels, both total, and unbound levels were within a range not normally associated with toxicity. The infusion was initially stopped at 6 h; from this time total ropivacaine plasma levels remained below those of all other trial participants. Unbound ropivacaine levels fell throughout the infusion period, to reach a level of ,0.02 mg litre 21 at 72 h.
No other episodes of potential local anaesthetic toxicity were encountered in subsequent subjects. There were no other TAP catheter related complications.
With the exception of one subject, who returned to theatre on Day 3 for management of surgical bleeding, plasma ropivacaine levels were collected on all subjects throughout the 72 h infusion.
Discussion
This is the first study assessing ropivacaine plasma concentrations during a continuous infusion into the TAP. Relatively high cumulative doses of ropivacaine (up to 2216 mg .72 h) and marked individual variability in responses were observed.
The toxicity of local anaesthetic agents is typically determined by studying i.v. infusions in healthy volunteers. These data are extrapolated to clinical scenarios involving extravascular local anaesthetic infusions; however, because the pharmacokinetics of local anaesthetics vary depending on the site of injection, 19 plasma concentrations causing toxicity during i.v. infusion might not be analogous to plasma levels observed during extravascular infusion. Knudsen and colleagues 20 evaluated toxic plasma concentrations of ropivacaine after infusions of i.v. ropivacaine in healthy volunteers. Neurological symptoms were observed at venous total ropivacaine concentrations as low as 0.5 mg litre 21 ; however differences in arterial and venous drug concentrations were observed because of a delay in establishment of a steady-state across tissue compartments. As the authors note, 'peripheral venous blood returning from poorly perfused sampling tissues during rapid i.v. administration is not representative of the distribution to, and concentration at, the site of action for central effects of local anaesthetics'. We believe that the more clinically relevant 'neurological toxicity range' for ropivacaine are the arterial sampled ropivacaine levels observed in Knudsen's study. The arterial sampled levels during i.v. infusion better approximate venous sampled levels after slower absorption from an extravascular location such as the TAP. In Knudsen's study, symptoms attributable to toxicity commenced in the arterial sampled range of 3.4-5.3 mg litre 21 .
The role of protein binding is important in local anaesthetic toxicity. After surgery, levels of a-acid glycoprotein increase, and consequently, there is increased protein binding capacity for local anaesthetics. This has been shown to stabilize unbound local anaesthetic concentrations in the presence of increasing total drug concentration during continuous infusion. As it is unbound local anaesthetic that determine pharmacodynamic and toxic effects, it is more useful to quote unbound plasma concentrations in discussing 'safe' plasma concentrations. 17 The quoted unbound ropivacaine range causing neurological toxicity in Knudsen's study was 0.34-0.85 mg litre 21 (arterial sample). 20 How do these ranges relate to our study? Four subjects had a total ropivacaine level between 3. The subject who developed symptoms consistent with local anaesthetic toxicity demonstrated an interesting, and previously reported phenomenon, of symptoms despite presumably safe drug concentrations. This subject had symptoms consistent with local anaesthetic neurotoxicity, but demonstrated low plasma concentrations of both total and unbound ropivacaine levels (,1.5 and 0.08 mg litre 21 , respectively, for the duration of the infusion). Other authors have identified that symptoms of systemic toxicity correlate poorly with plasma concentrations of local anaesthetic. 21 -23 A potential explanation for this phenomenon is that patients vary in their sensitivity to local anaesthetics. There are several limitations of this study. First, we did not objectively assess degree of nerve blockade. Therefore, there is no certainty that all the catheters remained in the TAP plane. Potentially catheters could have migrated into highly vascular muscle during the infusion period.
Secondly, we did not analyse unbound ropivacaine levels for the first 24 h of infusion. However, the study by Griffiths and colleagues 12 complements our study in providing more detailed consideration of the first 24 h after TAP blocks.
In conclusion, given the potential for high plasma concentrations from a bilateral infusion technique, attention should be paid to individualized dosing strategies. Further studies into the safety and efficacy of this technique are justified.
